Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: A meta-regression analysis

HIV Medicine

Volumn 9, Issue 10, 2008, Pages 849-857

  Mills, E J ^a   Kelly, S ^b   Bradley, M ^b   Mollon, P ^b   Cooper, C ^c   Nachega, J ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF OTTAWA   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV AIDS; Meta analysis; Surrogate markers

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FATALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 55649096214     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00643.x     Document Type: Review

References (29)

1. Albert JM, Ioannidis JP, Reichelderfer P et al. Statistical issues for HIV surrogate endpoints: Point/counterpoint. An NIAID workshop. Stat Med 1998; 17: 2435-2462.
2. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: A meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12: 1823-1832.
3. Easterbrook PJ, Emami J, Moyle G, Gazzard BG. Progressive CD4 cell depletion and death in zidovudine-treated patients. J Acquir Immune Defic Syndr 1993; 6: 927-929.
4. Reekie J, Mocroft A, Neaton J, Lundgren JD. Clinical outcomes in clinical trials of anti-HIV treatment. Future HIV Ther 2007; 1: 251-258.
5. Rodriguez B, Sethi AK, Cheruvu VK et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296: 1498-1506.
6. Hughes MD. Initial treatment of HIV infection: Randomized trials with clinical end points are still needed. J Infect Dis 2006; 194: 542-544.
7. Lima VD, Hogg RS, Montaner JS. Presenting plasma HIV RNA level and rate of CD4 T-cell decline. JAMA 2007; 297: 805-806; author reply 806-807.
8. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788.
9. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 2002; 288: 2432-2440.
10. Bucher H, Guyyatt GH, Cook D, Holbrook A, McAlister F. Surrogate Outcomes. In: Guyatt G, Rennie D, eds. The Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Publications, 2002.
11. Lacchetti C, Guyatt G. Surprising results of randomized controlled trials. In: Guyatt G, Rennie D, eds. The Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago, IL: AMA Publications, 2002.
12. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis. AIDS Res Hum Retroviruses 2000; 16: 1123-1133.
13. Lagakos SW, Hoth DF. Surrogate markers in AIDS: Where are we? Where are we going? Ann Intern Med 1992; 116: 599-601.
14. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 count-guided interruption of antiretroviral treatment. New Engl J Med 2006; 355: 2283-2296.
15. Dickersin K, Larson K. Establishing and maintaining an international register of RCTs. In: The Cochrane Collaboration Handbook. Oxford: Update Software, 1996.
16. Schrey G. The HIV Trial Guide, a Guide to Major Studies, Trials and Acronyms of HIV Antiretroviral Therapy 1985-2005. Van Zuiden Communications B.V.: Alphen 2005.
17. Mills EJ, Nachega JB, Buchan I et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA 2006; 296: 679-690.
18. Mills EJ, Nachega JB, Bangsberg DR et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3: E438.
19. Mills E, Wu P, Gagnier J, Heels-Ansdell D, Montori VM. An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol 2005; 58: 662-667.
20. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 2005; 26: 480-487.
21. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-371.
22. Sheehe PR. Combination of log relative risk in retrospective studies of disease. Am J Public Health Nations Health 1966; 56: 1745-1750.
23. Harrigan PR, Hogg RS, Dong WW et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-347.
24. Hill AM, DeMasi R, Dawson D. Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther 1998; 3: 139-145.
25. Guyatt GH, Cranney A, Griffith L et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin N Am 2002; 31: 659-679, xii.
26. Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
27. El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
28. Moore DM, Hogg RS, Yip B et al. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350cells/μL. HIV Med 2006; 7: 383-388.
29. Grimes DA, Schulz KF. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005; 105: 1114-1118.